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ABSTRACT 
 
The focus of this experiment was to test the possible anti-depressant effects of ketamine 
in a novel model of alcohol withdrawal-induced depression in mice. In this model, inbred 
mice show long-term strain-dependent reductions in locomotor (running wheel) activity 
after chronic intermittent ethanol exposure via vapor chambers. Since wheel-running is 
rewarding and has antidepressant effects, we believe that reduced locomotion following 
ethanol withdrawal may reflect a depression-like syndrome resembling that seen in many 
abstinent alcoholics.  Nevertheless, in a previous experiment we were unable to reverse 
this locomotor deficit using Desipramine, a norepinephrine-selective reuptake inhibitor 
with behavioral activating properties.  Since low-dose ketamine has demonstrated rapid-
onset antidepressant effects in both human patients and animal models, we tested the 
ability of single ketamine injections to increase wheel-running in ethanol-withdrawn 
mice.  Preliminary results indicate that ketamine was ineffective in this model, at least at 
the dose and treatment regimen employed. 
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INTRODUCTION 
    Alcoholism and/or harmful drinking affects an estimated 17 million Americans (CDC, 
2009).  Globally, it is the leading risk factor of premature death among persons 15-49 
years old. Heavy drinking can lead to dependence, which in humans, is generally 
characterized by more than 12-14 drinks per week (NIAAA, 2013). Cessation of drinking 
once dependent, leads to a disorder called Alcohol Withdrawal Syndrome. 
 Alcohol withdrawal syndrome (AWS) is often characterized in a solely 
physiological manner. However, it is strongly associated with affective behavioral 
disturbances such as increased anxiety and poor mood. The severity of withdrawal varies 
greatly by individual. Furthermore, the temporal scale of alcohol withdrawal syndrome is 
broken down into three parts: acute, early abstinence, and protracted abstinence. Acute 
withdrawal refers to the first seven days post-withdrawal, early abstinence begins at the 
end of acute withdrawal continues up until eight weeks post-withdrawal, and protracted 
abstinence is any time after those eight weeks, lasting for years.  
 Acute withdrawal is the most widely studied area of alcohol withdrawal 
syndrome. In humans, this phase refers to the initial few days after the initial withdrawal 
until the seven days post-withdrawal. During this stage, the nervous system is 
hyperexcitable. Symptoms include tremors, autonomic nervous system instability, 
tremors, and seizures (Heilig, 2010). Disturbed sleep and circadian rhythms are also 
characteristic of acute withdrawal (Heilig, 2010). Additionally, acute alcohol withdrawal 
syndrome increases hyperventilation, anxiety, and craving for alcohol. The intensity of 
these symptoms is positively correlated to eventual relapse in protracted abstinence 
(Roeloffs, 1985).   
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  Following the acute withdrawal period is early abstinence. Early abstinence is 
generally characterized by the weeks, up to eight weeks, following the initial withdrawal. 
In this stage, persistent anxiety, poor mood, and sleep disruption are very prevalent 
(Heilig, 2010).  Anxiety levels have been show to decrease 3-6 weeks after the 
discontinuation of alcohol (Schuckit and Hesselbrock, 1994).  
 The third stage of abstinence, on the order of months to years after the initial 
withdrawal is protracted abstinence. Protracted abstinence is marked by affective 
instability. Trivial situations may initiate a very negative behavioral effect.  The stress 
from these encounters triggers many alcohol abusers to crave alcohol and relapse (Sinha 
and Li, 2007). Sleep and circadian disruptions continue into this stage of alcohol 
withdrawal (Heilig, 2010). The intensity and persistence of these sleep and circadian 
disruptions is positively correlated to alcohol relapse (Drummond et al, 1998). 
 Most animal models have focused on the acute withdrawal period. In rodents, 
protracted abstinence, after chronic exposure to ethanol has a negative effect, just as 
humans. Alcohol-withdrawn mice lack novelty-seeking behavior and increase 
environmental habituation behavior, suggesting increased anxiety-like behavior.  
(Fukushiro et al, 2011).  These studies also show that locomotor activity, as measured by 
the open-field test and home-cage running wheels, decreases after chronic ethanol 
exposure (Logan et al, 2010; Kliethermes et al, 2005).  Some have argued that placing 
mice in a novel home-cage with a running wheel is, in fact, a measure of anxiety or 
fatigue, not behavioral depression (Stanford, 2007). This confound, though, is not a 
probable factor in running-wheel activity. In anxiety-like behavioral tests, very little 
reduction in baseline locomotor activity has been seen (Kliethermes, 2005). Therefore, 
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although there may be a relationship between anxiety and locomotor activity, it is one 
that will not contradict any observed information. 
Neurobiology of Chronic Ethanol 
It is now well-known that ethanol acts upon the GABAA and NMDA-glutamate 
receptors (Chandler et al, 1993; Mehta and Ticku, 1995; Mehta and Ticku, 1999). GABA 
is the most widespread inhibitory neurotransmitter. The GABAA receptor is a ligand-
gated chloride ion channel. Activation of GABAA leads to inhibitory effects and 
contributes to inhibitory post-synaptic potentials (IPSP) (Sigel and Steinmann, 2012).  On 
the contrary, glutamate is the most abundant excitatory neurotransmitter in the 
mammalian brain. The NMDA receptor is a ligand-gated cation channel and is the 
predominant mechanism for controlling memory function and synaptic plasticity (Fei et 
al, 2009). The NMDA-R is activated when it binds to glutamate and the membrane is 
depolarized; it is both voltage-gated and ligand-gated (Scheetz and Constantine-Paton, 
1994).  However, this can occur with the aid of α-amino-3-hydroxy-5-methylisoxazole-
proprionic acid/kainate (AMPA/KA) receptors, another subtype of glutamate receptor. 
Often, they are in the same spatial and temporal range (Scheetz and Constantine-Paton, 
1994).  Furthermore, NMDA-R allows for the influx of calcium ions, activating localized 
calcium-dependent cascades and beginning the early steps of long term potentiation 
(Bliss and Collingridge, 1993).  
 Chronic ethanol exposure upregulates NMDA-R, in both increased function and 
number of receptors (Follesca and Ticku, 1995). Rani and Ticku (2006) cultured CIE 
neurons from rats and found that CIE exposure, and subsequent withdrawal, upregulated 
the subunits of NMDA-R, NR2B, but not NR1. Rani and Ticku suggest the CIE exposure 
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alters ion gating abilities, synaptic plasticity and transmission, hyperexcitability, and 
neurotoxicity. Chronic ethanol GABAA functions are downregulated via decreased 
mRNA expression (Rani and Ticku, 2006).  Withdrawal from CIE induces GABAA 
receptor responsiveness to decrease extrasynaptically and increase in the synapses of the 
hippocampus (Liang et al, 2006). These effects may contribute to long-term alcohol 
dependence. The decrease in GABA neurotransmission during withdrawal directly 
inhibits dopaminergic neurons in the substantia nigra (Glue and Nutt, 1990). This 
inhibition leads to increase dopamine transmission, which may be correlated with 
increased severity of withdrawal symptoms (Heinz et al, 1996).  
Chronic Intermittent Ethanol 
 Howard Becker and colleagues (Becker and Hale, 1993; Becker et al, 
1997) developed a mouse model that represents alcohol dependence in mice. His studies 
use specialized chambers to force mice to become physically dependent on ethanol, since 
they will not otherwise become dependent on their own. Each individual chamber 
connects to a one-liter bottle of 95% ethanol, which then mixes into ethanol vapor and air 
in a tube, in order to force ethanol-saturated air into and out of the chamber. The levels at 
which ethanol vapor is pumped is determined by an air and ethanol gauge. Animals 
exposed to this protocol for six-to-nine days had the greatest effect when measuring 
withdrawal, by means of handling-induced convulsions (Goldstein, 1972).   
Goldstein (1972) also found that in a 24-hour period, 16-hours of ethanol vapor, 
followed by 8-hours of fresh air, created the most intense withdrawal periods. This 
ethanol/air cycle, called the “kindling hypothesis,” states that the period of detoxification 
allows for the severity of each subsequent withdrawal period to increase (Brown et al, 
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1988; Becker et al, 1997). Thus, by the end of the treatment, the mice have already 
experienced multiple withdrawal periods, making the final withdrawal period the most 
severe.  
Logan et al (2010) used a chronic intermittent ethanol (CIE) procedure to 
determine the effects of alcohol withdrawal on circadian rhythms and locomotor activity. 
Logan exposed the C57/B6 mice to a four-day CIE protocol, in which each day consisted 
of 16 hours of ethanol vapor, followed by 8 hours of air. Throughout CIE exposure, mice 
were entrained to LD 12:12. At the end of four days, mice were placed into running-
wheel cages in constant darkness. Logan discovered that there was a significant running-
wheel deficit for seven days post-treatment, but resumed baseline activity on day eight. 
There was no significant change in circadian rhythmicity. The experiment suggested that 
the persistent effects of alcohol withdrawal induced depression may be quantifiable 
through running wheels and circadian rhythms. 
Logan et al (2012), a follow-up study, mainly compared withdrawal-sensitive 
C3H mice to the B6 mice used in the previous experiment. He ran the C3H mice and B6 
mice through 3 cycles of the 4-day CIE protocol, and additionally ran the C3H mice 
through one cycle of the protocol. Directly after CIE exposure, mice were placed into 
running wheel cages in constant darkness. Logan found that C3H mice showed 
reductions in running wheel activity for up to 30 days in both the 1-cycle and 3-cycle CIE 
treatment, whereas B6 mice displayed hypolocomotion for seven days in both treatments 
(Appendix A). C3H mice had significantly shortened free running periods, but B6 mice 
did not show any change in free running period. These findings, as Logan suggests, are 
likely due to genetic differences. The circadian alterations, moreover, may contribute to 
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the hypolocomotion, suggestive of behavioral depression. Lastly, his novel approach 
using running wheels as a motivational, reward-seeking measure of depression may be a 
simpler alternative to the current electrical stimulation.  
Running Wheels 
Previous data has shown that most laboratory mice will spontaneously run within 
five to ten minutes of first introduction to the wheels.  Most mice will run regularly 
within five days of continuous exposure to the wheels, under otherwise normal conditions 
(Sherwin, 1998). Other contributing factors, such as age, oestrus, social conditions, and 
rearing environment, can be neglected, since all mice are approximately the same age (+/- 
3 days), are male, and were housed in identical environments, with ample food and water 
supply.  
In order to quantify a locomotor deficit, wheel-running can be used. Voluntary 
wheel-running is not just a generalized activity for mice (Sherwin, 1998); rather, it 
activates reward pathways within the mouse brain that have positive, lasting effects 
(Greenwood, 2011).  Voluntary running-wheel activity in mice is comparable to 
voluntary exercise in humans- improving physical and mental health conditions 
(Eikelboom, 1998). Often, drugs of abuse initiate the same reward pathways, leading to 
addiction and depression. Running wheels, in mice, have been shown to reverse this 
effect, thus can be considered an antidepressant activity (Brene et al, 2007). Moreover, 
running-wheel activity is shown to be anxiolytic, across several anxiety measures, such as 
light-enhanced startle, open-field test, stress-induced hyperthermia, social interaction 
(Salam et al, 2009). Based upon this evidence, low running wheel activity can be 
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construed as a measure of behavioral depression, analogous to human behavioral 
depression. 
Two strains of mice are typically used in our lab for ethanol experiments: 
C3H/HeJ and C57/B6. The mice we chose, strain C3H/HeJ, are prone to anxiety-like 
behaviors, as shown through a variety of standardized tests (Milner and Crabbe, 2008). 
During ethanol exposure, they show high blood ethanol concentration, relative to B6 
mice (Metten and Crabbe, 2005). Throughout withdrawal periods, C3H have severe 
handling-induced convulsions (HICs), also referred to as seizures, the second highest of 
fifteen tested strains (Metten and Crabbe, 2005). The C3H mice are much less alcohol-
preferring and have more severe withdrawals, consequently, making them the ideal strain 
for this experiment. 
Antidepressant Treatments 
Previous studies in our lab have shown that mice exposed to the chronic 
intermittent ethanol (CIE) protocol, followed by subsequent withdrawal, show decreased 
locomotor activity, as measured through the use of running-wheels (Logan et al, 2012) 
(Appendix A).  The induced hypolocomotion is interpreted to be a state of behavioral 
depression, analogous to human depression. Therefore, it would be logical to investigate 
possible treatments, namely, clinical antidepressants. If the antidepressants were to work, 
we could then expect to see an increase in running-wheel activity of the treated animals.  
Prior to the current experiment, we tested the effects of desipramine on alleviating 
alcohol-withdrawal induced depression. Desipramine is a tricyclic antidepressant (TCA) 
and is commonly used to treat endogenous depression. It inhibits the reuptake of 
norepinephrine and, to a small extent, serotonin (Mayo Clinic Laboratories, 2014).  In 
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humans, Desipramine usually takes about two or three weeks to take effect. In mice, 
desipramine has been linked to improving depression-like states, such as cytokine levels 
(Kubera et al, 2001).  In our laboratory’s tests, we were unable to see a significant 
difference in running-wheel activity when ethanol-withdrawn mice were treated with 
desipramine (Rosenwasser et al, unpublished). We concluded, then, that desipramine 
neither alleviated nor reversed the effects of alcohol withdrawal induced depression. 
Another type of antidepressant has been of recent interest to researchers: 
ketamine. Ketamine is a street drug and a veterinary anesthetic. The drug was created in 
1962 to be used as a fast-acting, battlefield anesthetic (Jansen, 2000).  Since then, it has 
made its way onto the illicit drug scene, where it can produce effects such as 
hallucinations, increased libido, elevated heart rate, and euphoria (Jansen, 2000). Today, 
ketamine is largely used as an animal anesthetic, when administered in high doses. At 
mid-dosage levels, it is psychotomimetic.  More recent studies, however, show that at 
very low doses, ketamine may be used as a putative antidepressant.   
Much is unknown about ketamine. Preliminary studies have shown that injections 
with low doses of ketamine (0.5mg/kg) may alleviate major depression disorder in 
patients who are unresponsive to common treatment (Murrough et al, 2013).  These 
patients responded to treatment within two hours of administration and lasted up to two 
weeks (Liebrenz et al, 2009).  Furthermore, patients showed low chance of relapse of 
depression, up to three months (Murrough et al, 2013). Ketamine acts as a N-methyl –D-
aspartate (NMDA) glutamate antagonist. Mice that develop helplessness (via learned 
helplessness, forced swim test) and subsequently treated with low dose ketamine show 
acute, yet sustained non-depression (Maeng et al, 2008). With all things considered, 
9 
	  
treating mice undergoing alcohol withdrawal with ketamine may serve to alleviate the 
hypolocomotion associated with alcohol withdrawal. 
Circadian Rhythms 
    Daily biological rhythms are run by an intrinsic clock. These rhythms are referred to as 
circadian rhythms and are driven by a biological clock. These rhythms unify almost all 
organisms, from unicells to brain cells (Lakin-Thomas and Brody, 2004; Welsh et al, 
1995). The study of them has emerged into a field of chronobiology. The daily period, 
usually a twenty-four hour period, can be stimulated to induce a phase change with 
stimuli (Brager et al, 2010). Recent interactions in human and animal research propose 
interactions between alcohol exposure and/or withdrawal with disruptions in the sleep 
and the circadian clock. Human alcoholics, in extended periods of protracted withdrawal, 
have been shown to have persisting chronobiological disruptions, leading to relapse 
(Drummond et al, 1998; Brower, 2003). Chronic intermittent ethanol (CIE) exposure 
fundamentally alters the circadian clock, as measured by free-running period and 
response to phase-shifting stimuli (Rosenwasser et al, 2005a,b).   
Rationale 
In humans, glutamate may play a large role in the pathophysiology of major 
depression disorder (MDD).  Studies have shown that glutamate levels increase in the 
cerebral spinal fluid (Levine et al, 2000) and increase in the brain (Hashimoto et al, 2007; 
Sanacora et al, 2004). Post-mortem protein assays have shown that the level of NMDA 
and AMPA receptors also decreased in the perirhinal cortex, though not the hippocampus 
or entorhinal cortex, in patients with MDD (Beneyto et al, 2007). Rodent models show 
similar results to that of humans. Mice characterized as “depressed,” by forced swim tests 
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and tail suspension tests in glutamate knockout mice, showed upregulation of the mGlu1 
subunit of the NMDA-R and downregulation of mGluR2,3,4, and 7 (Tokita et al, 2012).  
Moreover, “depressed” rats showed decreased levels of NMDA-R in the many regions of 
the brain, including the cerebral cortex, amygdala, hypothalamus, hippocampus, and 
prefrontal cortex (Tokita et al, 2012).  Reversely, both rats and mice were “depressed” 
when given an NMDA-R knockout, using various genetic mutations (Tokita et al, 2012).  
 Ketamine acts as a non-competitive NMDA-R antagonist. At subaneshetic levels, 
it is a putative antidepressant. In mice, it reduced “depression” symptoms, as tested by 
learned helplessness and forced-swim tests (Tokita et al, 2012).  Ketamine prevents the 
excessive influx of calcium, thus, preventing cellular damage. The drug enhances the 
firing rate of glutaminergic neurons, in addition to the increased presynaptic release of 
glutamate (Moghaddam et al, 1997).  In low doses, ketamine increases dopamine release 
in the prefrontal cortex, but this upregulation is secondary to the activation of AMPA/KA 
(Moghaddam et al, 1997). Furthermore, Moghaddam suggest that AMPA/KA activation 
may enhance the antagonistic effects of ketamine on NMDA-R. Ketamine-induced 
upregulation of AMPA/KA- glutamate receptor may allow rapid intracellular signaling 
and greater synaptic plasticity (Duman and Voleti, 2011). Another proposed mechanism 
and target of the antidepressant treatment is increased expression of brain-derived 
neurotrophic factor (BDNF) and the subsequent mRNA. The BDNF promotes 
neuroplasticity, neurogenesis, and neuroprotection, all which enhance the antidepressant 
effects (Duman and Voleti, 2011). 
Ethanol acutely antagonizes NMDA receptors. Ethanol withdrawal has biphasic 
effects on glutamatergic transmission that may account for the central nervous system 
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hyperexcitability during acute withdrawal and the persistent depression associated with 
protracted abstinence.  
 Due to ketamine’s ability to upregulate AMPA/KA-glutamate receptors and the 
hyperexcitable state of the central nervous system during protracted ethanol abstinence, 
there may be a possibility of ketamine counteracting the effects of ethanol withdrawal. 
We hypothesized that ketamine may be effective in preventing or alleviating the effects 
of withdrawal-induced behavioral depression.  
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MATERIALS AND METHODS 
Subjects and Apparatus 
     Upon arrival in the laboratory, six to eight week old male C3H/HeJ mice (Jackson 
Laboratories, Bar Harbor, ME) were weighed and housed in groups of five in standard 
mouse cages. Food (ProLab RMH3000, Lab Diet, St. Louis, MO) and tap water were 
readily available. Cages were placed in large (60x36x60cm) Plexiglass vapor inhalation 
chambers, two cages (ten mice) per chamber.  
 
Procedures 
     Half of the mice (n=20) were exposed to an eight-day chronic intermittent ethanol 
vapor, while the other half (n=20) were exposed to eight days of plain air. All mice were 
maintained under LD 12:12 conditions throughout the CIE protocol. Twenty-four hours 
after the last exposure to ethanol, animals were injected with single dose of 10mg/kg, i.p., 
ketamine or saline.  
Thereafter, mice were placed into individual cages, equipped with running-wheels 
(diameter 35cm). Each running-wheel cage was housed in a sound-and-light protected 
enclosure with a standard light bulb. Acclimation to wheel-running was measured and 
analyzed using ClockLab (Actimetrics Co., Wilmette, IL). All mice were maintained 
under constant darkness, in order to measure the free running period. The free running 
period is using daily wheel turns.  Mice continued to have free access to tap water and 
food.  
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Chronic Intermittent Ethanol 
     The CIE protocol is based on the research of Becker et al. (1997) and Logan et al  
(2010).  The protocol consists of eight daily cycles of 16 hours of ethanol vapor exposure 
followed by 8 hours of plain air exposure. The onset of ethanol vapor exposure was 
concurrent with the onset of 12 hours of darkness (LD 12:12).  Ethanol vapor exposure 
ended four hours into the light cycle. Control mice were exposed to plain-air for all eight-
days, but remained on the same LD 12:12 cycle as the CIE mice. Ethanol (95%) was 
pressurized into vapor and constantly pumped at a rate of 10-12 L/min (Logan et al, 
2010).  
     Directly before each ethanol exposure, experimental animals were administered an 
injection with 1.6mg/kg of ethanol, and 68.1mg/kg pyrazole HCl. Pyrazole is an alcohol 
dehydrogenase inhibitor that initiates intoxication and stabilizes  
blood ethanol concentration 
(BEC) (Becker and Hale, 
1993).  Pyrazole was 
dissolved in 20% w/v ethanol 
solution and administered i.p. 
at 10mL/kg. Control animals 
were injected with the same 
quantity of pyrazole dissolved 
in a 0.9 % saline solution. 
 
 
Image 1: Vapor Chambers. Mice exposed to CIE protocol were 
housed in chambers above.  Each chamber connects to a pump 
that regulates the alcohol and air mixture input. 
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Ethical Considerations 
     This experiment was conducted with approval of the University of Maine Institutional 
Animal Care and Use Committee (IACUC).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
	  
 
RESULTS 
 
 Figure 1, below, shows the gradual increase of running-wheel activity in all 
groups of mice five weeks after final CIE treatment. Activity levels were expressed as 
wheel-turns per day and subjected to a three-factor analysis of variance (ANOVA), with 
ethanol treatment (vs. air), ketamine treatment (vs. saline) and post-treatment week as 
factors.   An initial analysis using all five post-treatment weeks showed a significant 
effect of weeks (F4,132 = 7.898, p < 0.001) indicating that activity levels increased over 
time, but no effects of either ethanol or ketamine treatments.  Nevertheless, a follow-up 
analysis restricted to the first three post-treatment weeks revealed a main effect of week 
(F2,72 = 6.747, p = 0.002) and a weeks-by-ethanol interaction (F4,132 = 4.116, p = 0.002).  
This result indicates that, as expected, activity levels increased more slowly in ethanol-
treated than in air-exposed mice over the first three post-treatment weeks.  Finally, we 
performed separate two-factor (ethanol, ketamine) ANOVAs for each post-treatment 
week, which showed a significant main effect of ethanol only at week 3 (F1,36= 4.435, p = 
0.042). 
The free-running period is the endogenous period of time (typically 24.0 hours) 
that the steers the mouse’s circadian rhythms. Baseline for these animals is determined by 
the control, which has a free-running period of approximately 23.7 hours (figure 2). 
Animals exposed to CIE treatment had a period of approximately 23.9 hours. Mice 
treated with only ketamine had an increased free-running period that nearly reached 24.2 
hours, whereas mice treated with ketamine and ethanol had period between standard air 
and standard ethanol, at 23.8 hours. This suggests that although there was an effect of 
ketamine in the air animals, it did not alleviate any effects of alcohol withdrawal in the 
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ethanol treated mice. A two-factor (ethanol, ketamine) ANOVA failed to detect any 
significant treatment effects on free-running circadian periods. 
 
 
Figure 1. C3H Acclimation to Running Wheel Activity. All display an increase in locomotor 
activity over the course of five weeks post-treatment weeks, as expected. There is a significant 
decrease in ethanol-treated animals (p=0.02) over the first post-treatment weeks. Ketamine does 
not alleviate symptoms of ethanol-withdrawal. 
 
Furthermore, the initial phase shows the endogenous circadian phase, measured in 
the first 24 hours of constant darkness. animals treated with saline and air have an initial 
phase of approximately 15 hours, whereas animals treated with saline and ethanol have 
an initial phase of approximately 16 hours (figure 3). This phase shift is expected due to 
the sleep-disrupting effects of ethanol withdrawal. Ketamine treated animals, however, 
display reverse effects. Animals treated with ketamine only had an initial phase of nearly 
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18 hours. On the opposite end of the spectrum, animals treated with CIE, followed by a 
ketamine injection, had an initial phase of about 11 hours. Two-factor (ethanol, ketamine) 
ANOVA revealed a significant ethanol-by-ketamine interaction (F1,36= 4.504, p = 0.041).  
This interaction was examined using post-hoc pairwise comparisons which showed that 
initial phase was significantly earlier (advanced) in the ethanol+ketamine group relative 
to all other groups.  This finding suggests that ketamine induced significant circadian 
phase-shifts only in ethanol-treated animals. 
             Figures 4 and 5 show a sample of daily running-wheel activity shifts over the six 
week length of the experiments. Ethanol-treated animals display a delayed phase shift 
lasting approximately three weeks post-initial withdrawal. After three weeks, the ethanol 
animals show the same phase shift the air mice did three weeks prior.  
 Throughout the CIE protocol, weights were measured every two days. Both 
groups, ethanol and air, lost small amounts of weight during the eight-day procedure (air: 
-1.625 grams; ethanol: -1.940 grams). 
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Figure 2. Free-Running period in Ethanol- and Ketamine-treated C3H mice. Mice  
exposed to CIE protocol, on average, had a slightly longer free-running period after the exposure. Mice 
exposed to air and ketamine had a longer period than all other groups combined. 
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Figure 3. Initial Phase of Ethanol- and Ketamine-treated C3H mice. The initial phase of CIE-exposed 
mice is slightly higher than those exposed to air. However, there is a large effect of ketamine, in both air 
and ethanol exposed mice. Ketamine, when injected into air animals, greatly increases the initial phase. On 
the contrary, when injected into ethanol-exposed animal, ketamine reduces the initial phase by 
approxiamtely 25%.  
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Figure 4. Air-exposed mouse actogram. Thissample actogram shows the gradual acclimation to running-
wheels in air-exposed control animals. The running-wheel activity is initially sparse, but gradually 
increases over six weeks. Their phase slightly changes over time, suggseting normal circadian rhythmicity. 
(Note: X-axis represents time in hours, with each zero starting the next consecutive day).  
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Figure 5. CIE-exposed mouse actogram. Thissample actogram shows the gradual acclimation to running-
wheels in CIE treatment animals. The running-wheel activity is initially sparse and very sporatic. At the 
end of week three, their phase begins to shift on a similar slope to control animals. The first three weeks 
remain in a stationary phase. (Note: X-axis represents time in hours, with zero starting the next consecutive 
day).  
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DISCUSSION 
 
      The discovered results are consistent with previous results from the lab. As shown in 
figure 1, there was a significant effect of ethanol three-weeks after the initial withdrawal 
period from CIE treatment. The post-withdrawal symptoms have the possibility of being 
linked to lethargy or malaise. Furthermore, mice show very slight reductions in body 
weight and food intake when treated with chronic intermittent ethanol (Kliethermes et al, 
2005). The ethanol-induced hypolocomotion suggests that ethanol-withdrawal state, as 
experienced by the CIE treated mice, may be analaogous to the depressive state that 
withdrawn human alcoholics may experience.  
      The acclimation to running-wheel activity is impaired in ethanol-exposed animals. 
Ethanol withdrawal is shown to induce hippocampal neurotoxicity (Stepanyan et al, 
2008). The slow acclimation to running-wheel activity may be from the withdrawal-
induced hippocampal function.  
     Rreduction in running-wheel activity may suggest that the CIE-exposed mice lack 
motivation in running. Running-wheel activity is intrinsically rewarding (Sherwin et al, 
1998). It has antidepressant and anxiolytic properties (Duman et al, 2008; Salam et al, 
2009). Moreover, it is genetically different from other ambulation methods (Rosenwasser 
et al, 1996). Therefore, the examination of  running-wheel activity may provide a unique 
measure of reward-seeking behavior in animal studies of ethanol withdrawal.  
     There was no main effect of ketamine. Although ketamine slightly raised the 
locomotor activity in air-treated mice, it did not affect the CIE-exposed mce. Ketamine, 
in small doses, can induce a hyperlocomotive state (Irifune et al, 1991), seen in the not-
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significant air animals. Ketamine did not alleviate the behavioral depression induced by 
alcohol withdrawal. 
    The failure of ketamine to alleviate these symptoms is surprising. Because alcohol 
withdrawal puts the brain in a hypersensitive state, it was expected that ketamine would 
relieve these symptoms by upregulating GABA. However, alcohol and ketamine both 
depress the central nervous sytem (Detsch and Kochs, 1997). The mechanism by which 
ketamine and alcohol interact is unknown. One may suggest that ketamine antagonizes 
the N-methyl-D-aspartate glutamate receptor, decreasing the levels of pre-synaptic 
glutamte, while alcohol withdrawal leaves NMDA receptors hypersensistive and with 
increased levels of the inhibitory neuron GABA.Ketamine is known to regulate 
AMPA/KA-glutamate receptors. This regulation is thought to be be the main mechanism 
of antidepressant treatment (Akinfiresoye and Tizabi, 2013; Maeng et al, 2008). Ethanol 
is a known AMPA-antagonist. Perhaps the combination of ethanol and ketamine 
antagonized AMPA and NMDA-receptors, resulting in no alleviation of the alcohol 
withdrawal induced depression.  
    In regard to chronobiology, ethanol alters the free-running period of mice. The ethanol- 
and ketamine-treated mice show and even short free-running period. Recent studies have 
shown that chronic ethanol intake alters free-running period in rodents (Brager et al, 
2010; Rosenwasser et al, 2005a,b). The circadian disruptions may contribute to the 
behavioral depression seen. There is evidence that ketamine may play a role in 
modulating CLOCK genes Bmal1, Per2, and Cry1 (Bellet et al, 2011). In our data, 
ketamine did not entrain the mice to a standard free-running period, suggesting that 
alternative mechanisms or interactions may be occuring. Ethanol-only treated animals do 
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not respond to circadian-entraining stimuli, such as light /dark cycles, as quickly as air 
animals do (see figures 4 and 5).  
    Overall, there was a main effect of alcohol on circadian rhythmicity and on behavioral 
depresion. This study repated our lab’s previous findings that CIE-exposure and 
subsequent withdrawal induces a hypolocomotive state that can be translated intop 
protracted abstinence of human withdrawal stage. At this stage, human alcoholics are 
most likely to relapse in stressful situations (Heilig, 2010). Ketamine did not alleviate 
these symptoms, as hypothesized. Although ketamine is currently being used as an 
antidepressant in clinical human research, based upon this study, it should not be 
suggested as an antidepressant to relieve withdrawal symptoms.  
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APPENDIX A 
 
 
Chart A. C3H/HeJ CIE Wheel-Running Activity (Logan et al, 2012). C3H/HeJ  
mice exposed to CIE protocol show significantly decreased wheel-running activity 
up to four weeks post-treatment. The ethanol withdrawal induced hypolocomotion  
serves as a model analog for human behavioral depression (anhedonia).  
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APPENDIX B 
 
 
 
Chart B. Effects of desipramine administration following CIE protocol (Rosenwasser, unpublished).  
When administered with desipramine (i.p.) following traditional CIE protocol, C3H/HeJ mice showed no 
difference in running-wheel activity. The CIE treatment, and subsequent ethanol withdrawal, produces a 
hypolocomotion in running wheel activity, as expected. 
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